Welch P J, Barber J R, Wong-Staal F
Immusol Inc., San Diego, CA 92121, USA.
Curr Opin Biotechnol. 1998 Oct;9(5):486-96. doi: 10.1016/s0958-1669(98)80034-7.
The possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic research and therapeutic applications. In the therapeutics area, they have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation.
设计核酶以切割任何特定靶RNA的可能性使其成为基础研究和治疗应用中有价值的工具。在治疗领域,它们已被用于靶向传染病中的病毒RNA、癌症中的显性癌基因以及遗传疾病中的特定体细胞突变。最值得注意的是,几种针对HIV患者的核酶基因治疗方案已进入1期试验。最近,核酶已用于转基因动物研究、基因靶点验证和信号通路阐明。